Top Markets
#1 DogBull DogBull +106.08%
#2 ADO Protocol ADO Protocol +50.83%
#3 Siacoin Siacoin +43.08%
#4 The Bitcoin Bull The Bitcoin Bull +38.16%
#5 MarsCoin MarsCoin +36.76%
#6 Ontology Gas Ontology Gas +25.44%
#7 UnifAI Network UnifAI Network +23.80%
#8 Glidr Glidr +23.51%
#9 Useless Coin Useless Coin +20.49%
#10 Falcon Finance Falcon Finance +17.59%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
Clover Biopharmaceuticals, Ltd. Clover Biopharmaceuticals, Ltd.

Clover Biopharmaceuticals, Ltd.

2197
Rank in Stocks #15713
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on... Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.
Share Price
$0.25841098
Market Cap
$335.38M
Change (1 day)
-2.42%
Change (1 year)
73.70%
Country
CN
Trade Clover Biopharmaceuticals, Ltd. (2197)

Category

Healthcare
Operating Margin for Clover Biopharmaceuticals, Ltd. (2197)
Operating Margin as of 2026 TTM: 0.00%
According to Clover Biopharmaceuticals, Ltd. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Clover Biopharmaceuticals, Ltd. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.57% -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.